Difference between revisions of "Drug index"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
| + | ==A== | ||
*[[Aldesleukin (Proleukin)]] | *[[Aldesleukin (Proleukin)]] | ||
*[[Alemtuzumab (Campath)]] | *[[Alemtuzumab (Campath)]] | ||
| Line 5: | Line 6: | ||
*[[Asparaginase (Elspar)]] | *[[Asparaginase (Elspar)]] | ||
*[[Azacitadine (Vidaza)]] | *[[Azacitadine (Vidaza)]] | ||
| − | + | ||
| − | + | ==B== | |
| − | + | *Bacillus Calmette-Guerin | |
| + | *Bendamustine | ||
| + | *Bevacizumab | ||
| + | *Bexarotene | ||
| + | *Bleomycin | ||
| + | *Bortezomib | ||
| + | *Busulfan | ||
| + | |||
| + | ==C== | ||
| + | *Cabazitaxel | ||
| + | *Capecitabine | ||
| + | *Carboplatin | ||
| + | *Carmustine | ||
| + | *Cetuximab | ||
| + | *Chlorambucil | ||
*[[Cisplatin (Platinol)]] | *[[Cisplatin (Platinol)]] | ||
| + | *Cladribine | ||
| + | *Clofarabine | ||
| + | *Cyclophosphamide | ||
| + | *Cytarabine | ||
| + | *Cytarabine Liposomal | ||
| + | |||
| + | ==D== | ||
| + | *Dacarbazine | ||
| + | *Dactinomycin | ||
| + | *Dasatinib | ||
| + | *Daunorubicin | ||
| + | *Daunorubicin Liposomal | ||
| + | *Decitabine | ||
| + | *Denileukin Difitox | ||
| + | *Docetaxel | ||
| + | *Doxorubicin | ||
| + | *Doxorubicin Liposomal | ||
| + | |||
| + | ==E== | ||
| + | *Epirubicin | ||
| + | *Eribulin | ||
| + | *Erlotinib | ||
| + | *Estramustine | ||
| + | *Etoposide | ||
| + | *Everolimus | ||
| + | *Estramustine | ||
| + | |||
| + | ==F== | ||
| + | *Floxuridine | ||
| + | *Fludarabine | ||
| + | |||
| + | ==G== | ||
| + | *Gefitinib | ||
| + | *Gemcitabine | ||
| + | |||
| + | ==H== | ||
| + | *Hexamethylmelamine | ||
| + | |||
| + | ==I== | ||
| + | *Ibritumomab | ||
| + | *Idarubicin | ||
| + | *Ifosfamide | ||
| + | *Imatinib | ||
| + | *Ipilimumab | ||
| + | *Irinotecan | ||
| + | *Ixabepilone | ||
| + | |||
| + | ==L== | ||
| + | *Lapatinib | ||
| + | *Lenalidomide | ||
| + | *Lomustine | ||
| + | |||
| + | ==M== | ||
| + | *Mechlorethamine | ||
| + | *Melphalan | ||
| + | *Mercaptopurine | ||
| + | *Methotrexate | ||
| + | *Mitomycin | ||
| + | *Mitotane | ||
| + | *Mitoxantrone | ||
| + | |||
| + | ==N== | ||
| + | *Nelerabine | ||
| + | *Nilotinib | ||
| + | |||
| + | ==O== | ||
| + | *Ofatumumab | ||
| + | *Oxaliplatin | ||
| + | |||
| + | ==P== | ||
| + | *Paclitaxel | ||
| + | *Paclitaxel Liposomal | ||
| + | *Panitumumab | ||
| + | *Peg-asparginase | ||
| + | *Pentostatin | ||
| + | *Porfimer | ||
| + | *Pralatrexate | ||
| + | *Premetrexed | ||
| + | *Procarbazine | ||
| + | |||
| + | ==R== | ||
| + | *Rituximab | ||
| + | *Romidepsin | ||
| + | |||
| + | ==S== | ||
| + | *Sipuleucel-T | ||
| + | *Sorafenib | ||
| + | *Streptozocin | ||
| + | *Sunitinib | ||
| + | |||
| + | ==T== | ||
| + | *Temozolmide | ||
| + | *Temsirolimus | ||
| + | *Teniposide | ||
| + | *Thalidomide | ||
| + | *Thioguanine | ||
| + | *Thiotepa | ||
| + | *Toitimomab | ||
| + | *Topotecan | ||
| + | *Trastuzumab | ||
| + | *Tretinoin | ||
| + | *Triptorelin | ||
| + | |||
| + | ==V== | ||
| + | *Vinblastine | ||
| + | *Vincristine | ||
| + | *Vinorelbine | ||
| + | *Vorinostat | ||
| − | [[Vesicant & irritant chemotherapy]] | + | ==[[Vesicant & irritant chemotherapy]]== |
| − | [[Antiemesis|Antiemetic support]] | + | ==[[Antiemesis|Antiemetic support]]== |
==Reference== | ==Reference== | ||
[http://hemonc.org/docs/chemotherapysequences.pdf Chemotherapy Order of Administration (ONS recommendations-PDF)] | [http://hemonc.org/docs/chemotherapysequences.pdf Chemotherapy Order of Administration (ONS recommendations-PDF)] | ||
Revision as of 16:31, 14 November 2011
A
- Aldesleukin (Proleukin)
- Alemtuzumab (Campath)
- Altretamine (Hexalen)
- Arsenic trioxide (Trisenox)
- Asparaginase (Elspar)
- Azacitadine (Vidaza)
B
- Bacillus Calmette-Guerin
- Bendamustine
- Bevacizumab
- Bexarotene
- Bleomycin
- Bortezomib
- Busulfan
C
- Cabazitaxel
- Capecitabine
- Carboplatin
- Carmustine
- Cetuximab
- Chlorambucil
- Cisplatin (Platinol)
- Cladribine
- Clofarabine
- Cyclophosphamide
- Cytarabine
- Cytarabine Liposomal
D
- Dacarbazine
- Dactinomycin
- Dasatinib
- Daunorubicin
- Daunorubicin Liposomal
- Decitabine
- Denileukin Difitox
- Docetaxel
- Doxorubicin
- Doxorubicin Liposomal
E
- Epirubicin
- Eribulin
- Erlotinib
- Estramustine
- Etoposide
- Everolimus
- Estramustine
F
- Floxuridine
- Fludarabine
G
- Gefitinib
- Gemcitabine
H
- Hexamethylmelamine
I
- Ibritumomab
- Idarubicin
- Ifosfamide
- Imatinib
- Ipilimumab
- Irinotecan
- Ixabepilone
L
- Lapatinib
- Lenalidomide
- Lomustine
M
- Mechlorethamine
- Melphalan
- Mercaptopurine
- Methotrexate
- Mitomycin
- Mitotane
- Mitoxantrone
N
- Nelerabine
- Nilotinib
O
- Ofatumumab
- Oxaliplatin
P
- Paclitaxel
- Paclitaxel Liposomal
- Panitumumab
- Peg-asparginase
- Pentostatin
- Porfimer
- Pralatrexate
- Premetrexed
- Procarbazine
R
- Rituximab
- Romidepsin
S
- Sipuleucel-T
- Sorafenib
- Streptozocin
- Sunitinib
T
- Temozolmide
- Temsirolimus
- Teniposide
- Thalidomide
- Thioguanine
- Thiotepa
- Toitimomab
- Topotecan
- Trastuzumab
- Tretinoin
- Triptorelin
V
- Vinblastine
- Vincristine
- Vinorelbine
- Vorinostat
Vesicant & irritant chemotherapy
Antiemetic support
Reference
Chemotherapy Order of Administration (ONS recommendations-PDF)